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Don't let the title fool you, this book gives a wide view of
the state of the field in HIV treatment world-wide and
includes some enticing discussions of potential targets
and strategies on the horizon. Given its wide range of top-
ics and its focus on more than just small molecule inhib-
itors of HIV, the title seems almost too restrictive. The
book is divided into 4 areas: Issues in Clinical Manage-
ment, Issues Related to Drug Resistance, Implementation
in Developing Countries, and New Antiviral Targets. As
such, it could be a good source of information for investi-
gators new to the field or those needing a quick source of
information in areas tangential to their main focus. As is
the case with many textbooks that attempt to describe rap-
idly moving fields, many of the areas covered in the book
contain newer information, and readers are advised to
investigate more recent publications in areas they may
find of interest.
With its emphasis on drug resistance, toxicity, and com-
plex dosing strategies, the section on clinical management
sets the stage for the remainder of the book by making the
case for the need for additional drugs and other anti-viral
strategies. A chapter on immune-based therapies was also
included in this section, focusing on clinical trial results
that involved the use of various cytokines to affect
immune and viral parameters. More attention here and in
the last section could have been paid to different delivery
systems as well as to strategies that target the innate
immune system. The third chapter in this section, on the
use of treatment interruption strategies to manage HIV
infection gave a complicated picture of the relevance of
this strategy in the HIV treatment armamentarium. More
recent studies of this approach, such as the recently
released interim results of the SMART study, only serve to
confirm that risks associated with treatment interruption
need to be considered in the design of any trial that incor-
porates this strategy.
The section on drug resistance was comprehensive to this
unpracticed eye. The extensive discussions on resistance
mutations in chapter 4 were reiterated to a large extent in
the following chapter. Here editorial assistance would
have been of value in paring down this information and
omitting redundancies. I found the section in chapter 4
on lethal mutagenesis as a potential therapeutic strategy
to be particularly interesting and recent additions to the
literature point to KP-1212 as a mutagenic nucleoside
with favorable activity in vitro. Conflicting accounts of
possible mitochondrial toxicity point to the need for
closer examination of this issue.
Chapters 6 and 7 gave informative overviews of the diffi-
culties inherent in implementing HIV treatment in devel-
oping countries. The chapter on prevention of mother-to-
child transmission was particularly enlightening.
The final section on new antiviral targets includes a com-
prehensive overview of entry inhibitors, and a discussion
of inhibitors of host factors. I found the latter discussion
to have been confusingly written in passages, missing in
certain critical details (what were the effects of NAC on
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viral load, a critical parameter in the testing of any drug
with potential anti-viral activities) and in need of editorial
assistance. But it left the reader with the correct impres-
sion of the relative lack of good, non-toxic inhibitors of
host factors. This section omits reference to recently
released data on promising phase I studies on the matura-
tion inhibitor PA-457, the first of its class to enter clinical
trials. The chapter on RNAi is a nice summary of the state
of the art in this rapidly emerging field. As was pointed
out by the authors, given the specificity of these molecules
and the inherent difficulties in delivering them to the cells
of interest, it is unclear whether this strategy will have an
impact as a therapy on a virus as heterogeneous and rap-
idly changing as HIV. What was quite clear was the value
of this approach as a basic research tool to examine the
role of the factor of interest. The final chapter, on clear-
ance of the latent reservoir, pointed out the difficulties
inherent in deleting this long-lived reservoir of infected
cells. Given that these cells do not transcribe or express
viral proteins in a way that is accessible to current retrovi-
ral inhibitors or immune-based strategies, the challenges
are indeed great but must be met if HIV is ever to be erad-
icated from the infected individual. Promising but prelim-
inary results of a recent clinical trial of the DNA
remodeling drug valproic acid were not discussed.
In sum, this book gives a balanced account of issues
related to the clinical management of HIV in both devel-
oped and developing countries. Additional glimpses are
provided of new developments of possible relevance to
HIV treatment. These offer hope that the pipeline of new
drugs and therapies will continue to expand to meet the
growing need imposed by the development of resistance
and toxicities associated with current therapies.